Background: Although the mammalian central nervous system contains numerous matrix metalloproteinases (MMPs), the significance of each MMP relative to nociception remains obscure. Working from the hypothesis that MMPs may be involved in activity-dependent reorganization during neuronal modulation, we explored the role of each MMP following neuropathological injury by establishing MMP expression profiles in a murine model for neuropathic pain. Methods: Sciatic nerves of adult male C57BL/6C mice were partially ligated, and their responses to mechanical and radiant heat stimulations were observed at 1, 3, 7, and 14 days. The expression of several nociception-related MMPs (MMP-2, MMP-9, MMP-12, MMP-17, and MMP-24) in the spinal cord was detected by immunohistochemical analysis, Western blotting, and real-time polymerase chain reaction. In addition, the potential of GM6001, a general inhibitor of MMP peritoneal administration, to modulate nociceptive pain responses in a chronic neuropathic pain model in mice was also investigated. Results: MMP-2, 9, 17, and 24, but not MMP-12, were expressed in the murine spinal cord. MMP-9 was constitutively expressed in neurons and microglial cells, immediately upregulated after nerve injury, and returned to baseline levels at day 3. Expression of MMP-2, MMP-17, and MMP-24 gradually increased after nerve injury. Morphologically, MMP-2-positive cells were glial-like cells. MMP-17 and MMP-24 expression was widespread in gray matter, neurons, and microglial cells, and concentrated in the marginal zone of the dorsal horn and in small capillaries. Peritoneal administration of GM6001 resulted in significantly attenuated thermal hyperalgesia and tactile allodynia induced by nerve injury. Conclusion: Expression of several nociception-related MMPs was differentially regulated both temporally and spatially following nerve injury. These results suggest that neuronal remodeling requires concerted expression of particular MMPs in specific temporal and spatial patterns, which may be necessary for neuronal plasticity and/or recovery.
Introduction
Matrix metalloproteinases (MMPs) are a family of zincdependent endopeptidases. Accumulated evidence indicates that most MMPs have unique tissue distributions and biological functions. 1e3 The influence of MMPs is widespread, affecting adhesion molecules, cytokines, receptors, and also having an impact on the pain system and the release of painrelated substances, including tumor necrosis factor-a (TNF-a) and substance P. 2, 4, 5 Several lines of evidence suggest that the mammalian central nervous system (CNS) contains numerous MMPs, and that their expression can be upregulated after an acute insult or during the peak pathological state of a chronic injury. 6e8 Moreover, the upregulated expression of MMPs during nerve injuries often leads to several undesirable outcomes. 9, 10 However, the importance of their sequential expression and their biological role during nociceptive signal transmission following injury remain obscure.
The participation of MMPs during nerve injury is supported by other reports in which MMPs were differentially distributed and expressed in both mouse and rat neuropathic pain models. 9, 11, 12 Therefore, one reasonable hypothesis that emerges from these findings is that MMPs may actively participate in different pathological states and may be involved in activity-dependent reorganization during neuronal modulation. To explore the role of different MMPs following neuropathological injury, the expression profiles of MMPs in a murine model of neuropathic pain would need to be established. This report documents the temporal and spatial expression of MMPs in the spinal cord following peripheral partial sciatic nerve ligation (PSNL) in mice.
Methods

Animals and preparation
Adult male C57BL/6C mice, 8e10 weeks old and weighing 15e20 g, were purchased from Charles River in Taiwan. All procedures were reviewed and approved by the Institutional Animal Care and Use Committee at Chang Gung Memorial Hospital, and animals were treated in accordance with the Ethical Guidelines for Investigations of Experimental Pain in Conscious Animals, as issued by the International Association for the Study of Pain. Animals were randomly assigned to one of two groups that were subjected to right-side PSNL or sham control. Thermal hyperalgesia and tactile allodynia were observed for 1, 3, 7, and 14 days after surgery. In parallel with behavioral experiments, the expression profiles of MMPs in the spinal cord were estimated by immunohistochemical analysis, Western blotting, and real-time polymerase chain reaction (PCR). During experiments, animals were housed in individual ventilation cages in a qualified satellite facility. Postoperative wound care was examined daily, and animals with signs of wound infection or dehiscence were excluded from the study. At the end of the protocol, all animals were killed by an overdose of pentobarbital (by peritoneal injection) with subsequent cervical dislocation.
Surgical procedures
The animal model for chronic neuropathic pain was prepared as previously described for rats and mice. 13, 14 All animals were anesthetized with 1.5e2% isoflurane, the right sciatic nerve was exposed at the upper thigh level, and half of the diameter of the nerve was tightly ligated using a 6e0 polydioxanone suture. Sham surgeries were also performed by exposing the sciatic nerve without ligation. After ligation, muscle and skin layers were closed and animals were allowed to recover in their cages.
Nociceptive tests
The measurement of pain behaviors has been previously described, and minor modifications were made to that protocol in the present study. 15, 16 In brief, animals (n ¼ 12/group) were placed individually on an elevated plastic mesh floor covered with a clear plastic cage and allowed to acclimate to the environment for at least 60 minutes. Withdrawal responses to punctuate mechanical stimulation were determined using calibrated Semmes-Weinstein Von Frey filaments (Stoelting, Wood Dale, IL, USA). Stimulation was applied to the distal portion of the plantar aspect of the hindpaw. Each stimulus was applied from 0 g to the point at which a withdrawal response was observed or until the cutoff value of 20 g was reached. These tests were repeated three times for each mouse, with a 5-minute resting period. The mean value of these tests was considered as the withdrawal threshold. Withdrawal latencies to heat stimulation were assessed by applying a focused radiant heat source (Model-336 IITC Paw and Tail Flick Analgesia Meter; IITC Inc., Woodland Hills, CA, USA). The heat stimulus was applied to the distal portion of the plantar aspect of the hindpaw. The cutoff value was set at 15 seconds. Each mouse was tested three times, with 5e10minute resting periods between each test, to obtain the average paw withdrawal latency.
Treatment with an MMP inhibitor
Different groups of mice (n ¼ 12/group) were treated with either GM6001, a general inhibitor of MMPs [Chemicon, Temecula, CA, USA; 100 mg/kg in 4% methylcellulose, intraperitoneally (i.p.)], or vehicle (4% methylcellulose, i.p.) 2 hours before PSNL or sham surgery, followed by additional treatment every 24 hours for an additional 3 days. The protocol of GM6001 treatment was determined according to a previous experimental report, with minor modifications. Subsequently, nociceptive behavior was observed for 1, 3, 7, and 14 days after the surgery.
Immunohistochemical analysis
Animals were anesthetized and killed at 1, 3, 7, and 14 days after nerve ligation and spinal cords were ejected from the vertebral column using a cold-saline-filled syringe. The L4eL5 spinal cord segments were fixed in 4% paraformaldehyde for 6 hours. After subsequent dehydration, samples were embedded in paraffin, sliced into 5-mm sections with an automatic microtome, immersed in xylene, and rehydrated. Rehydrated tissue sections were incubated in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6.0) for 30 minutes at 95e100 C for antigen retrieval, followed by treatment with 0.3% hydrogen peroxide and blocking with 10% normal goat serum (NGS; Vector Laboratories, Burlingame, CA, USA). Tissue section samples were then incubated with rabbit polyclonal anti-MMP-2 (1:1000; Torrey Pines Biolabs, San Diego, CA, USA), anti-MMP-9 (1:2000; ANAWA, Zurich, Switzerland), anti-MMP-12, anti-MMP-17, or anti-MMP-24 (1:500, BioVision, Mountain View, CA, USA) antibody and diluted in phosphatebuffered saline (PBS) containing 0.3% Triton-X 100 and 3% NGS at 4 C for 24e36 hours. After washing, the sections were incubated in biotinylated goat anti-rabbit immunoglobulin G (IgG) secondary antibody (Vector Laboratories, Burlingame, CA, USA) at 1:200 using an Elite VECTASTAIN ABC kit (Vector Laboratories, Burlingame, CA, USA). Sections were developed with 0.05% diaminobenzidine in PBS for 3e10 minutes. Images were captured using a digital camera (Nikon DXM 1200 with Eclipse E800; Nikon Instruments Inc., Melville, NY, USA).
To examine coexpression of MMPs in various cells in the spinal cord, sections were respectively incubated with different MMP antibodies and with goat anti-Iba1 (1:400; Abcam, Cambridge, MA, USA), mouse antineuronal-specific nuclear protein (NeuN) (1:1000; Millipore Bioscience Research Reagents, Temecula, CA, USA), or mouse anti-glial fibrillary acidic protein (anti-GFAP; 1:5000, Millipore Bioscience Research Reagents) antibody overnight at 4 C under gentle agitation. Sections were then incubated with the respective secondary antibodies: donkey antigoat (1:100), goat antirabbit conjugated with Rhodamine Red-X (1:200); goat antimouse, donkey antirabbit, and goat antirat conjugated with fluorescein isothiocyanate (1:200; all from Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Nonspecific staining was determined by excluding primary antibodies. Thereafter, sections were washed and cover slips were mounted on the glass slides with ProLong antifade medium (Molecular Probes, Inc., Eugene, OR, USA). Images were captured using a fluorescence microscope operated by Case Data Manager Expo 4.5 software (Leica DM2500; Leica Microsystems Inc., Houston, TX, USA).
Western blot analysis
The ipsilateral halves of spinal dorsal horns were weighed, homogenized in buffer A [20 mM 4-(2-hydroxyethyl)-1piperazine ethanesulfonic acid (HEPES), pH 7.5, 150 mM NaCl, 3 mM MgCl 2 , 1 mM b-mercaptoethanol, 5 mg/mL leupeptin, 5 mg/mL pepstatin A, 1 mg/mL aprotinin, and 0.1 mM phenylmethylsulfonyl fluoride], and centrifuged (15,000 g, 4 C) for 10 minutes. The supernatants were collected and stored at À80 C for later analysis. The pellets were resuspended and agitated in buffer B (25 mM HEPES, pH 7.4, 150 mM NaCl, and 1% Triton X-100) at 4 C for 4 hours and then centrifuged (15,000 g, 4 C) for 10 minutes. The supernatants were collected and stored at À80 C for further analysis. Each sample was first separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (30 mg of total protein per lane) and then transferred onto nitrocellulose membranes (Hybond polyvinylidene difluoride membranes; Amersham Pharmacia Biotech, San Francisco, CA, USA). After blocking with 5% low-fat milk for 1 hour at room temperature (22e24 C), membranes were incubated with an individual primary antibody (1:1000 for anti-MMP-2, 1:2000 for anti-MMP-9, and 1:500 for anti-MMP-12, 17, and 24) and anti-b-actin antibody (1:10,000, Santa Cruz Biotechnology, Inc., San Francisco, CA, USA) for another hour and then subjected to three washes. Membranes were further incubated with horseradish peroxidase-conjugated goat antirabbit IgG secondary antibodies (Jackson ImmunoResearch Laboratories, Inc.) at room temperature for 1 hour, followed by three washes. Finally, the immune complexes were detected using an ECL plus chemiluminescent kit (Amersham Pharmacia Biotech). The intensity of the immunoreactive bands was quantified using ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA) and normalized to b-actin in each sample.
Total RNA isolation and quantitative real-time PCR
Different groups of animals (n ¼ 6/group) were killed at 0, 1, 3, 7, and 14 days after PSNL for quantitative real-time PCR analysis as described in previous reports. 16, 17 Spinal cords were harvested and homogenized in 0.8e1 mL TRIzol (Invitrogen, Carlsbad, CA, USA). Total RNAs were extracted using the PureLink Micro-to-Midi Total RNA Purification System (Invitrogen). Spectrophotometric analysis was used to determine the total RNA concentrations of each sample, and all RNA samples were pretreated with DNase I (Invitrogen) before complementary DNA (cDNA) synthesis. First-strand cDNAs of each sample were reverse transcribed using the SuperScript III first-strand synthesis SuperMix system (Invitrogen). Specific primer for MMPs (MMP-2, MMP-9, MMP-12, MMP-17, and MMP-24) were designed for quantitative PCR using Oligo 6.67 (Molecular Biology Insights Inc., West Cascade, CO, USA) ( Table 1 ). The primers for the b-actin gene were also designed and used as an endogenous control for normalization. Each reaction was performed with 10 mL of Master Mix (DyNAmo, Flash Probe qPCR Kit; Finnzymes, Espoo, Finland), 1 mL of a mix containing two primers (10 mM each), and a template (0.2 mM) for each specific cDNA sample. The quantitative PCRs were conducted using the Chromo Table 1 Sequences of the gene-specific primers used for analysis by quantitative real-time PCR.
Gene
GenBank accession numbers Primer forward (5 0 to 3 0 ) Primer reverse
4 Four-Color Real-Time System (MJ; Bio-Rad Laboratories, Hercules, CA, USA). Linearity and efficiency of PCR amplification were assessed using standard curves generated by increasing amounts of cDNA. Melt-curve analyses were also conducted to estimate consistency of product formation and amplification of nonspecific products. The threshold for detection of PCR products was set in the log-linear phase of amplification, and the threshold cycle (C T ) was determined for each reaction. The levels of the target messenger RNAs (mRNAs) were quantified relative to the level of the housekeeping gene (b-actin) using the comparative C T (DC T ) method for each sample. Finally, the relative mRNA expression was presented as a ratio of the baseline expression level (0 days).
Statistical analysis
All data were expressed as mean AE standard deviation. Changes recorded from behavioral experiments as well as changes in protein-band intensity and in real-time qPCR results were tested with two-way analysis of variance with time points as a within-subjects factor, followed by Dunnett tests for multiple comparisons at individual time points. The results of flow cytometry were analyzed using ManneWhitney U tests to test specific hypotheses about differences between each test group and its corresponding control group. Statistical analysis was conducted using GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA). Statistical results were considered significant if p < 0.05.
Results
Mice subjected to PSNL demonstrated reduced withdrawal latency in response to nociceptive stimuli
The response time at the nerve lesion site (ipsilateral hindpaws) to nociceptive stimuli was assessed and compared with those collected from sham-operated animals. Fig. 1 shows that the mean thresholds did not differ between groups before PSNL. Mice subjected to PSNL demonstrated a significant reduction in withdrawal latency to both thermal and mechanical stimuli from 1 to 14 days after PSNL.
PSNL elicited increasing expressions of MMPs in the corresponding segments
Immunoreactivities of MMP-2, -9, -17, and -24 were detected in the spinal cords of mice receiving PSNL (Fig. 2) . Expression of MMP-2, 17, and -24 gradually increased after nerve injury. Conversely, MMP-9 was constitutively expressed and immediately upregulated after nerve injury, returning to baseline levels at day 3. MMP-12 expression was not detected in spinal cord samples at any time point. The observed MMP expression patterns were further supported at the mRNA and protein levels by real-time PCR (Figs. 3e6B) and Western blotting (Fig. 7) . These results indicated lower levels of MMP-2, -9, -17, and -24 in the sham control as compared with the PSNL groups.
Peritoneal administration of GM6001, a general inhibitor of MMPs, resulted in significantly attenuated thermal hyperalgesia and tactile allodynia induced by nerve injury
To establish whether peritoneal administration of an MMP inhibitor could modulate nociceptive pain responses, withdrawal latencies and thresholds to heat and punctuate mechanical stimulation were measured in animals treated with GM6001, a general inhibitor of MMPs, or vehicle in PSNL, or sham control animals. Results indicated that before treatment, mean withdrawal latencies did not differ between GM6001- treated and vehicle-treated groups. In subsequent post-PSNL days, withdrawal latencies and thresholds were substantially increased in the paws of GM6001-treated animals but not in vehicle-injected animals. When compared with vehicle-treated animals, GM6001-treated animals demonstrated a statistically significant ( p < 0.05) increase in withdrawal latencies and thresholds, which were maintained for the duration of the experiment (Fig. 1 ). However, treatment with GM6001 did not alter the threshold to stimulus-evoked response in sham surgery animals. These data suggest that animals treated with GM6001 demonstrated significantly attenuated thermal hyperalgesia and tactile allodynia induced by PSNL.
Temporally regulated differential expression of MMPs
Further analysis based on immunohistochemical results revealed that there were substantial differences in the expression patterns between each of the MMPs (Fig. 2 ). MMP-9 was constitutively expressed before PSNL, immediately upregulated after nerve injury ( Fig. 2-B2) , and returned to baseline during days 7e14 (Fig. 2-B4 and B5) . These observations were further supported by the mRNA and protein assays, where noticeable expression of MMP-9 was detected during days 1e3 (Figs. 4B and 7) . Conversely, the expression patterns of MMP-2, -17, and -24 gradually increased after nerve injury, and their peak expression was mainly detected in later phases. This pattern of expression was also confirmed by the results of our Western blotting and real-time PCR analysis, where the expression of MMP-2, -17, and -24 in the spinal cord was progressively upregulated after nerve ligation throughout the entire time course studied (Figs. 3B,5B,6B, and 7). In contrast to the other MMPs, the expression of MMP-12 at the mRNA and tissue levels was not detected over the entire time course in either the control or sciatic nerve ligation groups (Fig. 2-C1eC5 ).
Spatially regulated differential expression of MMPs
Substantial differences in the cellular expression patterns between each of the MMPs were also detected (Fig. 2) . The expressions of MMP-2 and MMP-9 were widespread in the gray matter, and the distribution pattern was even. They were mainly expressed in cell bodies, as opposed to interstitial areas within the gray matter. Moreover, cells with positive immunoreactivities to the MMP-2 antibody were morphologically glial like (Fig. 3A) , and the MMP-9 antibody positive cells were mostly neuron like (Fig. 4A ) and predominantly located in laminae I and II of the dorsal horn. The expression patterns of MMP-17 and MMP-24 were also widespread in the gray matter but predominantly localized to the marginal zone of dorsal lamina (Figs. 5 and 6A) . In addition to their expression in neuron-like cells, MMP-17 and MMP-24 were also observed in the small capillary vasculature and the matrix of the dorsal horn (Figs. 5 and 6A). These differences in cellular expression patterns were further supported by double immunostaining demonstrating MMP-2 expression in GFAPpositive astrocytes (Fig. 8I ) but not in neurons or microglial cells ( Fig. 8A and E) . MMP-9, MMP-17, and MMP-24 were expressed in neurons ( Fig. 8B, C, and D) as well as in microglial cells (Fig. 8F, G, and H) but not in astrocytes (Fig. 8J, K, and L) .
Discussion
In this study, the differential expression profiles of several pain-related MMPs (MMP-2, -9, -12, -17, and -24) were established in mice following PSNL. In addition, each of these MMPs demonstrated distinct temporal and spatial reactions following sciatic nerve injury. As these MMPs have been implicated in pathological pain development, 9,11,12,18e20 the alteration of their expression upon PSNL reflected their roles in the neuropathological process involving both neurons and glial cells. 10,21e25 The distinctive expression pattern of each MMP indicated a dedicated MMP machinery, which was differentially controlled and organized to modify and remodel the pathological process of neuropathic injury.
Our results showed that MMP-2 was constitutively expressed at a low level in sham animals and that its expression was increased over the first 2 weeks following injury. These findings are in contrast to recent data collected from both rat peripheral nerve and spinal cord injury models, in which upregulation of MMP-2 was observed at later stages of injury. 9, 19, 26 Comparing the spatial and temporal expression patterns, the results of the present study showed a distribution and pattern of MMP-2 expression similar to those in previous reports, with the exception that the expression level was consistently and gradually increased after injury. Although MMP-2 is a well-known member of the gelatinase family and is responsible for degradation of several pain-related mediators such as TNF-a, interleukin-1b (IL-1b), and substance P, 2 its role in neuropathic pain remains controversial. For example, local application or i.p. injection of an MMP inhibitor may reduce the level of neuropathic pain. 27, 28 Conversely, intrathecal administration of exogenous MMP-2 to the spinal cord produced analgesic effects in a rat model of acute pain. 18 A recent study demonstrated that intrathecal administration of MMP-2 was sufficient to produce neuropathic pain via IL-1b cleavage and astrocyte activation. 29 These results are consistent with findings from the present study, which demonstrated MMP-2 expression predominantly in astrocytes relative to neurons. Therefore, MMP-2 may play an important role in the inflammatory and neuropathic pain processes.
In the present study, continual low-level expression and subsequent upregulation of MMP-9 was observed over the first 3 days after PSNL. This increased expression of MMP-9 in the injured peripheral nerve and spinal cord has been demonstrated in rat peripheral nerve and spinal cord injury models. 9, 10, 19, 29 Expression in the early stage of injury supports the hypothesis that MMP-9 participates in the inflammatory response to neuropathic pain via IL-1b cleavage and microglial activation. 29 However, results from the present study revealed that the upregulation of MMP-9 was detected mainly in neurons of the dorsal horn. Specifically, this upregulation was detected predominantly in laminae I and II, in which the cellular components mainly comprised sensory neurons. Known as gelatinase-B, MMP-9 cleaves numerous substrates (TNF-a, IL-1b, interferon-g, and substance P) to generate active mediators and participates in the inflammation process by cleavage of these proteins. 2, 30 Plausibly, an MMP-9 deficiency could affect axonal outgrowth, migration, and apoptosis in the developing brain and promote neural regeneration. 2, 22, 31, 32 Results from several reports have demonstrated that suppression of MMP-9 under pathological conditions via different interventions resulted in attenuation of the severity of disease and preservation of organ function. 10, 12, 27, 28, 33 Conversely, MMP-9 has also been postulated to play a protective role during pathological conditions. 34, 35 Thus, the controversial role of MMP-9 remains unsolved. The results of the present study were in line with data collected from MMP-9 knockout (KO) mice, in which the MMP-9 deletion protected peripheral nerve fibers by preservation of myelin basic protein levels and reduced spontaneous pain behaviors in a murine model of peripheral nerve damage. 36 Additional research will be required in order to more fully elucidate the role(s) of MMP-9 in the CNS.
In contrast to previous studies using a spinal cord injury model, in which the MMP-12 transcript was shown to be upregulated at the lesion epicenter 5 days after injury, 19 MMP-12 expression was not detected in any of the spinal cord samples in the present study. As MMP-12 KO mice were less sensitive to smoking injury and the overexpression of human MMP-12 augmented inflammatory arthritis in transgenic rabbits, 8, 37 a role for MMP-12 during inflammation is well established. However, the discrepancy between data from previous reports and those from the present study may be related to the source of MMP-12. MMP-12, mainly produced by macrophages, is not detectable in normal adult tissues but may be induced rapidly in tissues undergoing remodeling. 38, 39 In the PSNL model, the activation of inflammatory cells is limited mainly to the peripheral nerve lesion, providing a plausible explanation for negative MMP-12 expression results in the spinal cord in the present study. MMP-12 has been implicated as a critical element for CNS development, as delayed myelin formation has been observed in MMP-12 null mice. 35 Therefore, further studies are needed to elucidate the role(s) of MMP-12 during neuropathic pain development.
MMP-17 was also detected immediately after PSNL, and its high expression was maintained throughout the experiment. MMP-17 is also known as a membrane type 4 MMP and was first identified in human breast carcinoma. 40 MMP-17 is expressed in the brain, spinal cord dorsal horn, colon, ovary, testes, and immune cells. 24 Despite its noticeable presence in the brain and spinal cord, very little is known of its physiological functions in the nervous system. However, it has been suggested that MMP-17 promotes TNF-a convertase activity, and that MMP-17 upregulation has been demonstrated in infection and inflammation models. 41e43 Therefore, it is plausible that MMP-17 may participate in the development of neuropathic pain, as the presence of MMP-17 would increase TNF-a production and thus contribute to the inflammatory responses in mice subjected to PSNL.
Similar to that for MMP-17, data from the present study showed that MMP-24 expression was observed immediately after PSNL and that its high expression level was maintained throughout the experiment. MMP-24 is a membrane type 5 MMP, recognized as a neuron-specific MMP because its expression is specifically detected in neurons of the CNS and peripheral nervous system, and has been implicated in neuronal axonal growth and plasticity. 11,44e46 Interestingly, recent evidence demonstrated that mice with genetically ablated MMP-24 demonstrated a lowered severity of neuropathic allodynia after PSNL or spinal cord transection. 11 This may be attributable to MMP-24-mediated degradation of chondroitin sulfate proteoglycans, which are abundant in neuronal tissues and inhibit neurite outgrowth. 23, 47, 48 Furthermore, histological tracing studies with cholera toxin B indicated that myelinated Ad afferent fibers sprouted and invaded from laminae III and VI to II in wild-type mice, whereas no sprouting and invasion of nerve fibers were observed in MMP-24-deficient mice. 11 These data suggest that MMP-24 may be involved in neuronal plasticity and modification during neuropathic pain development.
The hypothesis that neuronal plasticity remodeling during chronic neuropathic pain requires the concerted expression of specific MMPs is plausible provided that both temporal and spatial differential expression of MMPs are necessary and beneficial to the plasticity or recovery of the CNS. 45 The results of the present study document the expression profiles of neuropathic pain-related MMPs, which may contribute to Fig. 7 . Quantification of the changes in MMP protein levels at different time points after PSNL. Equal amounts (30 mg) of total protein extract were prepared at different time points, and expression profiles of MMP-2, -9, -17, and -24 in animals following PSNL were detected. b-actin was used as an endogenous control for normalization of the amount of total protein in each sample (*p < 0.05 relative to control). MMPs ¼ matrix metalloproteinases; PSNL ¼ partial sciatic nerve ligation.
future mechanistic studies addressing the role of each MMP during neuropathic pain development.
